The global human papillomavirus vaccine market size was valued at $3,892.7 million in 2021 and is projected to reach $10,823.0 million by 2030, growing at a CAGR of 12.4% from 2022 to 2030.
As the prevalence of human papillomavirus diseases grows, so does the market for human papillomavirus vaccines. The development of new HPV vaccines, as well as increased initiatives by government and commercial organizations for early screening and vaccination, are propelling the human papillomavirus (HPV) vaccine market forward. The rising incidence of HPV-related malignancies in the anal, oropharynx, and genital regions, as well as increased demand for HPV vaccinations to help decrease infections, are expected to keep the market growing steadily in the coming years.
Healthcare expenditures, on the other hand, are skyrocketing, with the drive toward prevention. Vaccination costs have risen from the single digits to triple digits several times over the last two decades, posing considerable issues for doctors and their patients while also putting a strain on public health funding.
The global human papillomavirus vaccine market trends is segmented on the basis of type, disease indication, industry vertical and region. Based on type, the market has been divided into tetravalent, nonavalent, and bivalent. Based on disease indication, the market has been divided into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Based on industry vertical, the market has been divided into public and private alliances, government entities, physicians, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this report include GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others.
As the prevalence of human papillomavirus diseases grows, so does the market for human papillomavirus vaccines. The development of new HPV vaccines, as well as increased initiatives by government and commercial organizations for early screening and vaccination, are propelling the human papillomavirus (HPV) vaccine market forward. The rising incidence of HPV-related malignancies in the anal, oropharynx, and genital regions, as well as increased demand for HPV vaccinations to help decrease infections, are expected to keep the market growing steadily in the coming years.
Healthcare expenditures, on the other hand, are skyrocketing, with the drive toward prevention. Vaccination costs have risen from the single digits to triple digits several times over the last two decades, posing considerable issues for doctors and their patients while also putting a strain on public health funding.
The global human papillomavirus vaccine market trends is segmented on the basis of type, disease indication, industry vertical and region. Based on type, the market has been divided into tetravalent, nonavalent, and bivalent. Based on disease indication, the market has been divided into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Based on industry vertical, the market has been divided into public and private alliances, government entities, physicians, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this report include GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others.
Key Market Segments
By Type
- Tetravalent
- Nonavalent
- Bivalent
By Disease Indication
- Cervical Cancer
- Anal Cancer
- Vulvar Vaginal Cancer
- Penile Cancer
- Oropharyngeal Cancer
- Others
By Industry Vertical
- Public and Private Alliances
- Government Entities
- Physicians
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- South Africa
- Rest of LAMEA
Key Market Players
- Merck & Co., Inc
- GlaxoSmithKline plc.
- Sanofi
- Johnson & Johnson
- AstraZeneca
- Serum Institute of India Pvt. Ltd
- Bharat Biotech.
- Xenetic Biosciences, Inc.
- Inovio Pharmaceuticals, Inc
- Novartis AG
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY TYPE
CHAPTER 5: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY DISEASE INDICATION
CHAPTER 6: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY INDUSTRY VERTICAL
CHAPTER 7: HUMAN PAPILLOMAVIRUS VACCINE MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Human Papillomavirus Vaccine Market," the human papillomavirus vaccine market was valued at $3.9 billion in 2021, and is estimated to reach $10.8 billion by 2030, growing at a CAGR of 12.4% from 2022 to 2030.There are around 100 types of the human papillomavirus (HPV), 14 of which are cancer-causing. According to the WHO, globally HPV 16 and 18 types cause over 70% of cervical cancers and pre-cancerous cervical lesions. The HPV vaccine market is being driven by rising rates of human papillomavirus (HPV)-related malignancies of the anus, vulva, vagina, penis, and oropharynx, as well as a growing need for infection prevention. Government spending in HPV vaccination programmes is also likely to fuel market expansion. Since June 2020, more than 55% of WHO Member States have begun HPV vaccination. Furthermore, growing healthcare infrastructure and spending in developing countries is anticipated to create hitherto unexplored opportunities for industry participants. By 2030, adequate increases in production capacity will have resulted in a stable HPV supply. This conclusion is contingent on the effectiveness and timeliness of ongoing clinical development projects, as well as the completion of existing HPV vaccine manufacturers' manufacturing capacity expansions, these factors are anticipated to boost the global human papillomavirus vaccine industry during the forecast period.
The global human papillomavirus vaccine market analysis is segmented on the basis of type, disease indication, industry vertical, and region. Based on type, the market has been divided into tetravalent, nonavalent, and bivalent. Based on disease indication, the market has been divided into cervical cancer, anal cancer, vulvar & vaginal cancer, penile cancer, oropharyngeal cancer, and others. Based on industry vertical, the market has been divided into public and private alliances, government entities, physicians, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this report include GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Sanofi S.A., Novartis AG, Serum Institute of India Pvt. Ltd., Bharat Biotech, Inovio Pharmaceuticals, Inc and Xenetic Biosciences, Inc. among others.
The report focuses on the global human papillomavirus vaccine market opportunity and the major products & applications, where human papillomavirus vaccines are utilized. It further highlights numerous factors that influence the market growth, such as forecast, trends, drivers, restraints, opportunities, and roles of different key players that shape the market. The report focuses on the overall demand for human papillomavirus vaccine in various countries, presenting data in terms of both value and volume. The revenue is calculated by proliferating the volume by region-specific prices, considering the region-wise differentiated prices.
IMPACT OF COVID-19 ON THE GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET OUTLOOK
- The pandemic has had a favorable impact on the global market for human papillomavirus vaccines. Despite the lockdown and tight government regulations imposed in response to the coronavirus epidemic, most healthcare personnel are performing their duties, and firms are investing extensively in vaccine development.
- The rising demand for HPV vaccine among the population is expected to fuel the market during a pandemic. Human papillomavirus is a lethal virus. Vaccine manufacturers and many other scientists are constantly working on the development of HPV vaccines as well as COVID viral symptoms, which is expected to increase the human papillomavirus vaccine market growth in the forecast years.
- Furthermore, Because of the COVID-19 pandemic, most medical, pharmacy, and biotech industries have focused on diagnostic kits, precautionary measures, and innovative coronavirus vaccines.
Key Findings of the Study
- The report provides an in-depth analysis of the global human papillomavirus vaccine market trends along with the current and future human papillomavirus vaccine market size.
- On the basis of type, the tetravalent segment emerged as the global leader in 2021 and is anticipated to hold the largest human papillomavirus vaccine market share during the forecast period.
- On the basis of disease indication, the cervical cancer segment emerged as the global leader in 2021 and is anticipated to be the largest market during the forecast period.
- On the basis of region, Asia-Pacific registered the fastest growth and is projected to maintain the position during the forecast period.
Companies Mentioned
- Merck & Co. Inc
- GlaxoSmithKline plc.
- Sanofi
- Johnson & Johnson
- Astrazeneca
- Serum Institute of India Pvt. Ltd
- Bharat Biotech.
- Xenetic Biosciences, Inc.
- Inovio Pharmaceuticals, Inc
- Novartis Ag
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | June 2022 |
| Forecast Period | 2021 - 2030 |
| Estimated Market Value ( USD | $ 3892.7 million |
| Forecasted Market Value ( USD | $ 10823 million |
| Compound Annual Growth Rate | 12.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
